CK0801

BIOLOGICAL3 trials

Sponsors

Cellenkos, Inc.

Conditions

Aplastic AnemiaBone Marrow DiseaseGuillain-Barré Syndrome

Phase 1

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Active, not recruitingNCT03773393

Cellenkos, Inc.Bone Marrow Disease

Start: 2019-05-30End: 2027-05-30Target: 18Updated: 2025-04-13

A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)

WithdrawnNCT03773328

Cellenkos, Inc.Guillain-Barré Syndrome

Start: 2022-11-30End: 2027-02-28Updated: 2023-01-04

Phase 2

CK0801 for Treatment of Aplastic Anemia

Not yet recruitingNCT07499102

Cellenkos, Inc.Aplastic Anemia

Start: 2026-08-03End: 2029-08-03Target: 12Updated: 2026-04-03

Related Papers

Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes

NEJM Evidence2024-05-2810 citations

Adoptive T Regulatory Cell Therapy Takes an Important Step

NEJM Evidence2024-05-28

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes

Blood2021-11-05

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis

Blood2020-11-053 citations

Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis

Blood2019-11-134 citations